Autolus Therapeutics plc has entered into a collaboration with Cellares Corp. to assess the feasibility of deploying the Cellares Cell Shuttle™ platform alongside its existing commercial manufacturing at the Nucleus facility in Stevenage, UK. The study will evaluate the automated, closed, single-use cartridge system’s ability to process up to 16 patient batches in parallel, with the goal of complementing Autolus’s current autologous CD19 CAR T cell production for its marketed therapy AUCATZYL® (obecabtagene autoleucel; obe-cel). This assessment follows receipt of the FDA’s Advanced Manufacturing Technology designation for the Cell Shuttle, which may streamline regulatory filings for Autolus’s future INDs and BLA supplements.

Autolus CEO Christian Itin, PhD, highlighted that demand for obe-cel could exceed the 10,000 annual patient doses currently supported by the Stevenage site if ongoing pediatric leukemia and autoimmune disease trials succeed. By integrating the Cell Shuttle’s end-to-end automation—which Cellares claims can deliver up to a ten-fold throughput increase per footprint and headcount compared with conventional facilities—Autolus aims to achieve more consistent batch quality, reduce per-dose manufacturing costs by an estimated 30%, and mitigate supply risks tied to manual workflows. The parallel deployment of Cellares’ Cell Q™ quality control platform could further accelerate release testing, cutting analytical turnaround times from days to hours.

Autolus is advancing obe-cel into pediatric r/r B-ALL trials and exploring indications in lupus and multiple sclerosis. Should those programs demonstrate durable responses, Autolus projects a 50–70% rise in manufacturing demand by 2028. The Cellares collaboration offers a capital-efficient path to scale beyond Stevenage without committing to greenfield expansions. This modular approach aligns with Autolus’s broader strategy to leverage external IDMOs for risk-sharing in later-stage assets, preserving internal resources for next-generation CAR T constructs targeting solid tumors and novel autoimmune targets.